Clinical Trials Directory

We are doing this study to find out if an investigational drug called tocilizumab (the study drug) will lead to better outcomes after lung transplantation when it is combined with standard anti-rejection medicines.

We are doing this research to learn more about whether taking a blood thinner, along with medications that prevent blood clots, improve outcomes in patients who develop atrial fibrillation (irregular heartbeat) after coronary artery bypass grafting surgery.

We are doing this study to compare treatment options for mitral valve regurgitation.

We are doing this study to find out if an investigational drug called CA-4948 is a safe and effective option for people with PCNSL. We want to know how well it works when it is combined with a drug called ibrutinib, which is commonly used to treat PCNSL.

This study includes up to three sessions that take about 5 to 6 hours in total. These sessions can happen all on the same day or be spread out over two months. People who join will first go through a screening and sign consent forms. They will then have an MRI scan and do head-tracking tasks using two different systems - one regular and one that uses computer vision. The study also includes finding the TMS motor threshold, which means using a small magnetic pulse to make a finger twitch. Participants will also receive sham TMS, which feels like real TMS but does not affect the brain, over a part of the brain called the prefrontal cortex. This study is testing a new, non-invasive system that does not need tracking tools on the head. It is made for research and does not involve any medicine or random group assignments.

We are doing this study to find out if an experimental drug called CT01681 (the study drug) is a safe and effective option for people who get CAR T-cell therapy as a treatment for diffuse large B cell lymphoma (DLBCL). We want to know if the study drug has the potential to lower or prevent certain side effects of CAR T-cell therapy. The possible side effects of CAR T-cell therapy that the study drug is being developed to protect against are called cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome. This study is enrolling people who will receive an available form of CAR T-cell therapy called YESCARTA.

We are doing this study to see if an experimental combination of drugs (D2C7-IT and 2141-V11) is a safe treatment for brain tumors.

To join this study, you must have already had surgery to remove as much of your tumor as possible. Once you are in the study, you will have another surgery to take a tiny piece of tissue and place a thin tube called a catheter in your brain where the tumor is. Through this tube, you will get a medicine called D2C7-IT for three days. Then you will get another medicine called 2141-V11 for about seven hours. About two weeks later, you will start getting shots of 2141-V11 under your skin near the lymph nodes in your head and neck. You will get another shot two weeks after that, and then shots every four weeks for up to a year. After that, you may keep getting shots every 4 to 6 weeks if you want.